Response Genetics, Inc – OTC:RGDXQ
Response Genetics stock price today
Response Genetics stock price monthly change
Response Genetics stock price quarterly change
Response Genetics stock price yearly change
Response Genetics key metrics
Market Cap | 116 |
Enterprise value | 9.20M |
P/E | N/A |
EV/Sales | 0.55 |
EV/EBITDA | -0.74 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.38 |
Revenue | 16.61M |
EBITDA | -12.74M |
Income | -14.84M |
Revenue Q/Q | -2.67% |
Revenue Y/Y | -8.05% |
Profit margin | -85.54% |
Oper. margin | -79.26% |
Gross margin | 40.49% |
EBIT margin | -79.26% |
EBITDA margin | -76.71% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeResponse Genetics stock price history
Response Genetics stock forecast
Response Genetics financial statements
| Jun 2014 | 4.28M | -3.16M | -73.86% |
|---|---|---|---|
| Sep 2014 | 4.46M | -3.90M | -87.41% |
| Dec 2014 | 4.07M | -3.57M | -87.64% |
| Mar 2015 | 3.79M | -4.20M | -110.9% |
| Jun 2014 | 12222650 | 7.20M | 58.98% |
|---|---|---|---|
| Sep 2014 | 16264622 | 14.25M | 87.64% |
| Dec 2014 | 13445084 | 14.61M | 108.7% |
| Mar 2015 | 10778229 | 15.71M | 145.81% |
| Jun 2014 | -3.18M | -90.46K | 455.91K |
|---|---|---|---|
| Sep 2014 | -4.30M | 49.27K | 8.07M |
| Dec 2014 | -3.71M | -16.28K | -30.77K |
| Mar 2015 | -1.88M | -2.41K | 1.42M |
Response Genetics alternative data
| Aug 2023 | 96 |
|---|---|
| Sep 2023 | 96 |
| Oct 2023 | 96 |
| Nov 2023 | 96 |
| Dec 2023 | 96 |
| Jan 2024 | 96 |
| Feb 2024 | 96 |
| Mar 2024 | 96 |
| Apr 2024 | 96 |
| May 2024 | 96 |
| Jun 2024 | 96 |
| Jul 2024 | 96 |
Response Genetics other data
-
What's the price of Response Genetics stock today?
One share of Response Genetics stock can currently be purchased for approximately $0.
-
When is Response Genetics's next earnings date?
Unfortunately, Response Genetics's (RGDXQ) next earnings date is currently unknown.
-
Does Response Genetics pay dividends?
No, Response Genetics does not pay dividends.
-
How much money does Response Genetics make?
Response Genetics has a market capitalization of 116 and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 7.89% to 18.04M US dollars.
-
What is Response Genetics's stock symbol?
Response Genetics, Inc is traded on the OTC under the ticker symbol "RGDXQ".
-
What is Response Genetics's primary industry?
Company operates in the Healthcare sector and Diagnostics & Research industry.
-
How do i buy shares of Response Genetics?
Shares of Response Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Response Genetics have?
As Jul 2024, Response Genetics employs 96 workers.
-
When Response Genetics went public?
Response Genetics, Inc is publicly traded company for more then 18 years since IPO on 5 Jun 2007.
-
What is Response Genetics's official website?
The official website for Response Genetics is responsegenetics.com.
-
Where are Response Genetics's headquarters?
Response Genetics is headquartered at 1640 Marengo Street, Los Angeles, CA.
-
How can i contact Response Genetics?
Response Genetics's mailing address is 1640 Marengo Street, Los Angeles, CA and company can be reached via phone at +32 3 224 39 00.
Response Genetics company profile:
Response Genetics, Inc
responsegenetics.comOTC
96
Diagnostics & Research
Healthcare
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Los Angeles, CA 90033
:
ISIN: US76123U1051
:
